NHNaoki Hiramatsu

Naoki Hiramatsu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Naoki Hiramatsu has a total of 355 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Physician-Level Variation in Adenoma Detection and Its Relationship with Procedural Volume: A 12-Year Longitudinal Analysis

    by Tomohide Kurahashi, Takuya Yamada, Atsushi Hosui, Naoki Hiramatsu

    Background/Objectives: Adenoma detection rate (ADR) is a central colonoscopy quality indicator, but the extent to which annual procedural volume explains physician-level ADR remains uncertain. We evaluated the association of procedural volume with ADR while separating within-physician annual changes from between-physician differences and explored rank-order persistence of physician-level ADR. Methods: We retrospectively analyzed 36,864 institutional ADR-eligible colonoscopies performed at a Japanese hospital from 2013 to 2024. The canonical dataset comprised 171 physician-year observations from 62 physicians. Weighted physician-year regressions decomposed log annual volume into within-physician and between-physician components. Case-level generalized estimating equations, grouped-binomial models, denominator-restricted analyses, influence analyses, a Bayesian hierarchical logistic model, and an exploratory restricted cubic spline analysis were used as complementary analyses. Results: The examination-weighted ADR was 52.7%, and median annual volume was 188 examinations. In the primary model, the within-physician coefficient was −0.003 (95% confidence interval [CI], −0.039 to 0.033; p = 0.882), corresponding to an estimated ADR difference of −0.19 percentage points per doubling of annual volume (95% CI, −2.69 to +2.31). The between-physician coefficient was 0.027 (95% CI, −0.012 to 0.067; p = 0.177), corresponding to +1.90 percentage points per doubling of usual volume (95% CI, −0.86 to +4.66). Grouped-binomial and denominator-restricted analyses did not identify a positive within-physician association. An exploratory pooled spline suggested curvature at lower volumes, but the overall spline association was not statistically significant. Conclusions: No positive within-physician association between annual procedural volume and ADR was identified. The between-physician estimate was imprecise and did not exclude a potentially meaningful positive association. Annual procedure counts should not be used alone as a surrogate for detection quality; direct longitudinal monitoring of ADR with attention to denominator size, uncertainty, case mix, and modifiable examination processes remains necessary.

  • Open Access

    Impact of Serum Albumin Levels on Prognosis and Recurrence in Patients with Hepatocellular Carcinoma

    by Naoko Hayata, Atsushi Hosui, Tomohide Kurahashi, Shigeki Suemura, Akane Namiki, Akino Okamoto, Takafumi Tanimoto, Hiroki Murai, Kohsaku Ohnishi, Motohiro Hirao, et al.

    Background: Liver function is a critical factor, both in the selection of treatment and in the prediction of prognosis in patients with hepatocellular carcinoma (HCC). The ALBI grade, introduced as a more objective method of assessing liver function, utilizes serum albumin (Alb) and total bilirubin (Bil) levels. Although albumin is widely recognized for its role in maintaining colloid osmotic pressure and regulating plasma volume, recent studies have implicated it in tumor progression, invasion, and metastasis. The purpose of this study is to determine the impact of serum albumin levels on overall survival (OS) and tumor invasion/metastasis in HCC patients with the same liver function (ALBI grade) at the time of diagnosis. Methods: In this study, 285 patients diagnosed with primary HCC at our institution from 2015 to 2019 were classified by ALBI grade and analyzed. Among them, 78 patients with ALBI grade 2 status were selected to evaluate the impact of albumin level. To further isolate the effect of albumin rather than bilirubin, patients in the ALBI grade 2 cohort were divided into two groups based on mean values of Alb (3.5 g/dL) and Bil (1.0 mg/dL). Alb normal group (Group A): Alb ≥ 3.5 g/dL, Bil ≥ 1.0 mg/dL (n = 42). Bil normal group (Group T): Alb < 3.5 g/dL, Bil < 1.0 mg/dL (n = 36). Liver function was almost the same in these two groups based on the ALBI grade. OS, progression-free survival (PFS), types of recurrence, and pathological findings were compared between the two groups. OS was analyzed by the log-rank test, and comparisons between the two groups were performed by the t-test and chi-square test, with p < 0.05 indicating statistical significance. Results: OS was significantly worse in Group T than in Group A before and after propensity score matching based on age, performance status, and HCC stage (p < 0.001 and p = 0.011). Among the 44 patients who received curative treatment (surgery or radiofrequency ablation), OS was also significantly worse in Group T (p < 0.001). An analysis of the recurrence patterns of 44 curatively treated patients revealed that Group T had significantly shorter PFS (p < 0.001), and all recurrence patterns were multiple (p = 0.002). Pathological analysis in 28 surgical patients showed that serosal invasion was present in significantly more patients in Group T (p = 0.003). Conclusions: Low serum albumin levels in patients with HCC indicate both liver dysfunction and increased tumor invasion and metastasis. Nutritional support and albumin supplementation may help reduce intrahepatic metastases and improve prognosis. Further studies are needed to explore the underlying mechanisms and therapeutic potential.


  • Open Access

    Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC

    by Atsushi Hosui, Naoko Hayata, Tomohide Kurahashi, Akane Namiki, Akino Okamoto, Kazuki Aochi, Munehiro Ashida, Takafumi Tanimoto, Hiroki Murai, Kohsaku Ohnishi, et al.

    Background/Objectives: Combination therapy with atezolizumab and bevacizumab (ATZ/BEV) is extremely effective and yields a high response rate in patients with hepatocellular carcinoma (HCC). In this study, the efficacy of adding locoregional therapy to ATZ/BEV in patients with stable disease (SD) HCC was investigated. Methods: One hundred five HCC patients who were treated with ATZ/BEV or lenvatinib (LEN) as first-line chemotherapy for unresectable HCC were evaluated on the basis of the modified RECIST criteria. SD patients whose initial antitumor effect was achieved received locoregional therapy, and the overall survival (OS) rate was assessed. Results: This study included 58 ATZ/BEV-treated participants and 47 LEN-treated participants. Twenty-eight SD patients (ATZ/BEV) and 20 SD patients (LEN) were identified. OS was significantly greater in ATZ/BEV-treated patients who also received locoregional therapy than in those who did not receive this additional therapy (p = 0.0343), whereas there was no difference between LEN-treated patients who also received locoregional therapy and those who did not. The locoregional therapy consisted of transcatheter arterial chemoembolization (TACE) and/or radiofrequency ablation (RFA). When assessing the add-on effect of TACE and/or RFA in the SD patients treated with ATZ/BEV, five patients were found to achieve CR. Conclusions: The addition of locoregional therapy, such as TACE/RFA, was found to affect SD patients. When a response is limited during ATZ/BEV therapy, it is important to consider the therapeutic option of adding locoregional therapy, as this additional treatment may contribute to improved prognosis via immune modulation.


  • Open Access

    Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral

    by Takayuki Matsumae, Takahiro Kodama, Yuki Tahata, Yuta Myojin, Akira Doi, Akira Nishio, Ryoko Yamada, Yasutoshi Nozaki, Masahide Oshita, Naoki Hiramatsu, et al.

    We evaluated the value of secreted glycoprotein thrombospondin-2 (TSP-2) to predict hepatocellular carcinoma (HCC) occurrence in chronic hepatitis C (CHC) patients after Hepatitis C virus (HCV) elimination by direct-acting antiviral agents (DAAs). A total of 786 CHC patients without an HCC history who achieved a sustained virological response (SVR) with DAAs were randomly assigned 2:1, with 524 patients as the derivation cohort and 262 patients as the validation cohort. Serum TSP-2 levels at the end of treatment were measured by enzyme-linked immunosorbent assay (ELISA). In the derivation cohort, the cumulative HCC rate was significantly higher in the high TSP-2 group than in the low TSP-2 group. Multivariate Cox proportional hazards analysis revealed that TSP-2, α-fetoprotein (AFP), and the fibrosis-4 (FIB-4) index were independent HCC risk factors. The area under the receiver operating characteristic curve (AUROC) of the score calculated from these three factors (AFT score) for predicting HCC was 0.83, which was significantly higher than that of each factor alone (TSP-2: 0.70, AFP: 0.72, FIB-4: 0.69). The AFT score was used to stratify patients according to the risk of HCC occurrence in the validation cohort. Lastly, in patients with a FIB-4 index < 3.25, the serum TSP-2 levels could be used to identify those patients with a high risk of HCC occurrence. Serum TSP-2 levels are a predictive biomarker of HCC occurrence in CHC patients after HCV elimination by DAA treatment. The AFT score using TSP-2, AFP, and the FIB-4 index may identify those who require HCC surveillance.


  • [A case of eosinophilic gastroenteritis caused after the use of Seprafilm®].

    by Takumi Kinomoto, Takuya Yamada, Yuhei Wakahara, Tomohide Kurahashi, Yukihiro Kusumoto, Toshio Yamaguchi, Yuka Sueyoshi, Motohiro Hirao, Atsushi Hosui, Naoki Hiramatsu

    Eosinophilic gastroenteritis is a fairly uncommon condition. It has been suggested that allergic reactions may have played a role in the development of this illness. The case of a 66-year-old woman who had a total hysterectomy due to a right ovarian tumor is described here. At this operation, a sodium hyaluronate carboxymethylcellulose bioresorbable membrane (Seprafilm®) was used. She was admitted to our hospital 47 days after the operation with abdominal pain. Laboratory data indicated elevated WBC (29450/μl) and eosinophilia (69.2%), and CT scan showed thickening of intestinal wall and ascites around there. Ascites cytology showed a significant increase of eosinophils (94.0%). She began taking oral steroids after being diagnosed with eosinophilic gastroenteritis, and her symptoms improved quickly. Despite the fact that Seprafilm® was thought to be a reliable and safe tool, it was suggested that a foreign body reaction to Seprafilm® could lead to eosinophilic gastroenteritis.

  • Open Access

    A Rare Case of the Jejunal Ectopic Pancreas Observed With an Endoscope

    by Ryohei Yamauchi, Takuya Yamada, Toshio Yamaguchi, Naoki Hiramatsu


  • Open Access

    Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites

    by Atsushi Hosui, Takafumi Tanimoto, Toru Okahara, Munehiro Ashida, Kohsaku Ohnishi, Yuhhei Wakahara, Yukihiro Kusumoto, Toshio Yamaguchi, Yuka Sueyoshi, Motohiro Hirao, et al.

    (1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed. However, it is still unclear whether this novel drug may improve long-term survival rates in cirrhotic patients with ascites. (2) Patients and methods: A total of 206 patients who responded insufficiently to conventional diuretics and were hospitalized for refractory ascites for the first time were retrospectively enrolled in this study. Among them, the first 57 consecutive patients were treated with conventional diuretics (the conventional therapy group); the latter 149 consecutive patients were treated with tolvaptan in addition to the conventional therapy (the tolvaptan group). (3) Results: The exacerbation of renal function was significantly milder in the tolvaptan group than in the conventional therapy group. The prognostic factors for survival in the tolvaptan group were being male, having hyperbilirubinemia, having a high blood urea nitrogen (BUN), and receiving high-dose furosemide at the start of tolvaptan treatment. The one-year and three-year cumulative survival rates were 67.8 and 45.3%, respectively, in patients with low-dose furosemide (p < 0.001). (4) Conclusion: Tolvaptan can improve survival in patients with cirrhotic ascites, especially when tolvaptan is started before high-dose furosemide administration.


  • Open Access

    Long-Term Zinc Supplementation Improves Liver Function and Decreases the Risk of Developing Hepatocellular Carcinoma

    by Atsushi Hosui, Eiji Kimura, Sumiko Abe, Takashi Tanimoto, Kousaku Onishi, Yukihiro Kusumoto, Yuka Sueyoshi, Kengo Matsumoto, Motohiro Hirao, Takuya Yamada, et al.

    Zinc plays a pivotal role in various zinc enzymes, which are crucial in the maintenance of liver function. Patients with chronic liver diseases (CLDs) usually have lower concentrations of zinc, which decrease further as liver fibrosis progresses. Whether long-term zinc supplementation improves liver function and reduces the risk of hepatocellular carcinoma (HCC) development remains unknown. Two hundred and sixty-seven patients with CLDs who received a zinc preparation (Zn-group; 196 patients), or who did not receive zinc (no Zn-treatment group; 71 patients), were retrospectively analyzed in this study. The Zn-group was divided into 4 groups according to their serum Zn concentrations at 6 months after the start of Zn treatment. Liver function significantly deteriorated in the no Zn-treatment group, while no notable change was observed in the Zn-group. The cumulative incidence rates of events and HCC at 3 years were observed to be lower in the Zn-group (9.5%, 7.6%) than in the no Zn-treatment group (24.9%, 19.2%) (p < 0.001). According to serum Zn concentrations, the cumulative incidence rates of events and HCC were significantly decreased in patients with Zn concentrations ≥ 70 µg/dL (p < 0.001). Zinc supplementation appears to be effective at maintaining liver function and suppressing events and HCC development, especially among patients whose Zn concentration is greater than 70 µg/dL.


  • Open Access

    Long-Term Zinc Supplementation Improves Liver Function and Decreases the Risk of Developing Hepatocellular Carcinoma

    by Atsushi Hosui, Eiji Kimura, Sumiko Abe, Takashi Tanimoto, Kousaku Onishi, Yukihiro Kusumoto, Yuka Sueyoshi, Kengo Matsumoto, Motohiro Hirao, Takuya Yamada, et al.

    Background and Aim: Zinc plays a pivotal role in various zinc enzymes, resulting in the maintenance of liver function. Patients with chronic liver diseases (CLDs) usually have lower concentrations of zinc, which decrease further as liver fibrosis progresses. It remains unknown whether long-term zinc supplementation improves liver function and reduces the risk of hepatocellular carcinoma (HCC) development. Patients and Methods: Two hundred sixty-seven patients with CLDs who received a zinc preparation (Zn-group; 196 patients), or who did not receive zinc (no Zn-treatment group; 71 patients) were retrospectively analyzed in this study. The Zn-group was divided into 4 groups according to their serum Zn concentrations at 6 months after the start of Zn treatment. Results: Liver function significantly deteriorated in the no Zn-treatment group, while no notable change was observed in the Zn-group. The cumulative incidence rates of events and HCC at 3 years were lower in the Zn-group (9.5%, 7.6%) than in the no Zn-treatment group (24.9%, 19.2%) (p<0.001). According to the serum Zn concentrations, the cumulative incidence rates of events and HCC were significantly decreased in patients with Zn concentrations ≥ 70 µg/dl (p<0.001). Conclusion: Zinc supplementation appears to be effective at maintaining liver function and suppressing events and HCC development, especially among patients whose Zn concentration is greater than 70 µg/dl.


  • Ultra‐deep sequencing analysis of resistance‐associated variants during retreatment with simeprevir‐based triple therapy after failure of telaprevir‐based triple therapy in patients with genotype 1 hepatitis C virus infection

    by Naoki Morishita, Naoki Hiramatsu, Tsugiko Oze, Ayako Urabe, Yuki Tahata, Ryoko Yamada, Takayuki Yakushijin, Atsushi Hosui, Sadaharu Iio, Akira Yamada, et al.

    Aim: Simeprevir (SMV)‐based triple therapy is an effective retreatment option following failure of telaprevir (TVR)‐based triple therapy. However, it is unclear whether the persistence of resistance‐associated variants (RAVs) induced by TVR‐based therapy may reduce the treatment effect of SMV‐based therapy.Methods: The factors associated with the treatment effect, including RAVs in the NS3 region, were examined in 21 patients with genotype 1b HCV infection who were treated with SMV‐based therapy after failure of TVR‐based therapy. Ultra‐deep sequencing was carried out to detect RAVs.Results: With the exception of one patient who discontinued treatment owing to adverse events, the sustained virologic response (SVR) rate was 50% (10/20). Ultra‐deep sequencing at the start of SMV‐based therapy revealed that TVR‐resistant variants were detected in six patients (29%), and no variants were observed at position 168. Cross‐resistance between TVR and SMV with low frequency was detected in only one patient, and this patient achieved SVR. Higher SVRs for SMV‐based therapy were attained in patients who discontinued treatment owing to the adverse effects of prior TVR‐based therapy (discontinuation 100% vs. non‐discontinuation 29%, P = 0.005), and patients who relapsed following prior pegylated interferon plus ribavirin therapy (relapse 100% vs. non‐response 20%, P = 0.007).Conclusions: In this study, ultra‐deep sequencing analysis revealed that TVR and/or SMV‐resistant variants may have no influence on the effect of SMV‐based therapy after failure of TVR‐based therapy. Patients who discontinued treatment owing to adverse effects of TVR‐based therapy and relapsers to previous pegylated interferon/ribavirin therapy would be good candidates for retreatment with SMV‐based therapy.